PMID- 31688130
OWN - NLM
STAT- MEDLINE
DCOM- 20200520
LR  - 20200520
IS  - 2162-5220 (Electronic)
IS  - 1710-3568 (Linking)
VI  - 30
IP  - 6
DP  - 2019 Nov/Dec
TI  - Triclosen and Its Alternatives in Antibacterial Soaps.
PG  - 352-357
LID - 10.1097/DER.0000000000000519 [doi]
AB  - BACKGROUND: In 2017, the Food and Drug Administration banned the marketing of 
      triclosan and triclocarban in antibacterial soaps, citing inefficacy and concerns 
      of systemic absorption and antibacterial resistance. As a result, there is an 
      anticipated decrease in the number of triclosan-containing products on the market 
      with an associated increase in antibacterial alternatives (eg, benzalkonium 
      chloride, benzethonium chloride, chloroxylenol, chlorhexidine) and cases of 
      allergic and irritant contact dermatitis. OBJECTIVES: The aims of the study were 
      to determine the extent that triclosan and triclocarban are being used in the 
      consumer and medical industries after the Food and Drug Administration marketing 
      ban and to appraise the risk of allergic contact dermatitis to triclosan 
      alternatives. METHODS: The National Drug Code Directory (NDCD), Google, Amazon, 
      Target, Walgreens, Walmart, CVS, and Colorado hospitals were surveyed for 
      antibacterial soap use. Antibiotics surveyed include triclosan, triclocarban, 
      benzalkonium chloride, benzethonium chloride, chloroxylenol, and chlorhexidine. 
      RESULTS: The most common antibiotics reported by the NDCD, consumer sites, and 
      Colorado hospitals were benzalkonium chloride, chloroxylenol, and triclosan, 
      respectively. Triclosan accounted for the second most prevalent antibacterial in 
      the NDCD- and consumer site-surveyed products. CONCLUSIONS: The triclosan 
      marketing ban may instigate increased exposure to triclosan alternatives. The 
      addition of antibacterial products to hand soaps does not improve soap 
      effectiveness and may cause harm by contributing to antibiotic resistance and the 
      development of allergic conditions. Additional studies are needed to elucidate 
      the benefits and harms of antibacterial soaps.
FAU - Rundle, Chandler W
AU  - Rundle CW
AD  - From the Department of Dermatology, University of Colorado, Aurora.
FAU - Hu, Sophia
AU  - Hu S
AD  - School of Medicine, University of Colorado, Aurora.
FAU - Presley, Colby L
AU  - Presley CL
AD  - School of Medicine, Rocky Vista University, Parker.
FAU - Dunnick, Cory A
AU  - Dunnick CA
AD  - From the Department of Dermatology, University of Colorado, Aurora.
AD  - Rocky Mountain Regional Veteran Affairs Medical Center, Aurora, CO.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dermatitis
JT  - Dermatitis : contact, atopic, occupational, drug
JID - 101207335
RN  - 0 (Anti-Infective Agents, Local)
RN  - 0 (Benzalkonium Compounds)
RN  - 0 (Carbanilides)
RN  - 0 (Soaps)
RN  - 0 (Xylenes)
RN  - 0F32U78V2Q (chloroxylenol)
RN  - 1VU15B70BP (Benzethonium)
RN  - 4NM5039Y5X (Triclosan)
RN  - BGG1Y1ED0Y (triclocarban)
RN  - R4KO0DY52L (Chlorhexidine)
SB  - IM
MH  - Anti-Infective Agents, Local/*adverse effects
MH  - Benzalkonium Compounds/adverse effects
MH  - Benzethonium/adverse effects
MH  - *Carbanilides
MH  - Chlorhexidine/adverse effects
MH  - Dermatitis, Allergic Contact/*etiology
MH  - Humans
MH  - Marketing/legislation & jurisprudence
MH  - Soaps/*chemistry
MH  - *Triclosan
MH  - United States
MH  - United States Food and Drug Administration
MH  - Xylenes/adverse effects
EDAT- 2019/11/07 06:00
MHDA- 2020/05/21 06:00
CRDT- 2019/11/06 06:00
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2020/05/21 06:00 [medline]
PHST- 2019/11/06 06:00 [entrez]
AID - 10.1097/DER.0000000000000519 [doi]
PST - ppublish
SO  - Dermatitis. 2019 Nov/Dec;30(6):352-357. doi: 10.1097/DER.0000000000000519.